GET DAILY SIGNALSWhy Is 22nd Century Group (XXII) Stock Down -17.36% Today?
Key Takeaways
- XXII shares fell roughly 17.4% in intraday trading, extending a sharp post-reverse-split slide.
- The primary driver is continued selling pressure following the company's 1-for-58 reverse stock split, which took effect November 5, 2026.
- Secondary pressures include ongoing equity-dilution concerns, weak second-quarter results, and persistent cash burn.
- The move reflects broader distress among micro-cap stocks using reverse splits to regain Nasdaq listing compliance.
- Traders are watching the company's third-quarter earnings, scheduled for release on November 16, 2026.
- For additional detail on valuation, review the Price Targets, Earnings, and Forecast pages for XXII.
- Explore Trending AI Robots to see which automated trading strategies are performing best under current market conditions.
Opening Summary
22nd Century Group, Inc. (XXII) is a biotechnology and tobacco products company best known as the developer of FDA-authorized, reduced-nicotine cigarettes under its VLN and Pinnacle VLN brands. Its shares were under heavy pressure on Thursday, trading near $1.60 during the session, down from a prior close of $1.93 — a decline of about $0.34, or roughly 17.4%. The selloff continues a multi-day deterioration that began after the company completed a 1-for-58 reverse stock split aimed at restoring compliance with Nasdaq Capital Market listing requirements.
Reverse Stock Split and Nasdaq Compliance
The most immediate catalyst behind the decline is the reverse stock split that became effective at 12:01 a.m. Eastern Time on November 5, 2026. Under the terms of the corporate action, every 58 outstanding shares were combined into one, reducing the share count from roughly 31.9 million to approximately 550,000 while leaving the number of authorized shares at 500 million. The company stated the split was undertaken solely to regain compliance with the Nasdaq Capital Market's continued listing standards.
While a reverse split mechanically raises the per-share price without changing the underlying value of the business, investors frequently interpret such large ratios as a sign of financial distress. The stock has continued to slide on a split-adjusted basis, reflecting sustained selling pressure rather than renewed confidence.
Dilution and Funding Pressures
Concerns over dilution have compounded the negative sentiment. In October 2026, the company raised approximately $4.7 million through an at-the-market stock sale, selling more than 15.7 million shares as part of a program permitting up to $18.8 million in common stock sales. With cash and equivalents reported at about $3.9 million at the end of the third quarter against a quarterly net loss of roughly $2.6 million, the prospect of additional capital raises remains a persistent overhang on the share price.
Weak Fundamentals and Recent Results
Fundamentals have also weighed on the stock. The company's second-quarter 2026 results significantly missed expectations, with revenue falling to $2.86 million versus forecasts near $7.48 million and a substantially wider-than-expected loss. Management has been shifting away from low-margin contract manufacturing toward branded reduced-nicotine products, a transition that has pressured near-term revenue even as the company reported preliminary third-quarter revenue growth of roughly 66% sequentially to about $4.8 million. The market has so far focused on the ongoing losses and cash burn rather than the improving top line.
Market Context and Trading Activity
The decline is consistent with the volatility typical of low-priced, micro-cap securities undergoing reverse splits. Post-split trading has shown elevated turnover relative to the reduced float, and the stock has remained firmly below its short-term moving averages, signaling weak technical momentum. The move appears driven primarily by company-specific factors rather than broad equity-market direction, as the stock's slide has diverged from the relatively stable tone in major indices during the session.
What Comes Next for XXII
Investors will turn their attention to the company's full third-quarter results, scheduled for release on November 16, 2026, when management is expected to provide updated financials and commentary on commercial progress for its VLN and Pinnacle brands. Key items to watch include any confirmation of Nasdaq compliance, further disclosures of capital-raising activity, and evidence that the retail rollout of reduced-nicotine products is translating into sustainable, higher-margin revenue. Risks remain substantial, including continued dilution, execution challenges, and the inherent volatility of a micro-cap equity trading on a split-adjusted basis.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. For traders seeking a systematic approach to navigating volatile markets, exploring the Trending AI Robots section can be a useful starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XXII in -31.11% downward trend, declining for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XXII declined for three days, in 429 of 441 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for XXII entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XXII just turned positive on October 06, 2026. Looking at past instances where XXII's MACD turned positive, the stock continued to rise in 26 of 35 cases over the following month. The odds of a continued upward trend are 74%.
XXII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.074) is normal, around the industry mean (-7.416). P/E Ratio (0.001) is within average values for comparable stocks, (12.996). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.595). Dividend Yield (0.000) settles around the average of (0.059) among similar stocks. XXII's P/S Ratio (0.166) is slightly lower than the industry average of (2.780).
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. XXII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XXII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a plant biotechnology company
Industry Tobacco